MY01 Welcomes Joe Kiani as Investor and Board Member to Accelerate Innovation in Connected Patient Monitoring

MONTREAL, Sept. 8, 2025 /PRNewswire/ -- MY01, an innovative medical technology company focused on transforming the diagnosis of limb perfusion injuries, today announced that Joe Kiani, founder of Masimo and a globally recognized leader in medical innovation, has invested in the company. Kiani, who also founded Willow Laboratories and is the co-founder and CEO of Like Minded Labs, will join the company's Board. 

"We are excited to welcome Joe Kiani as an investor and board member at MY01," said Charles Allan, CEO of MY01. "His track record in leading innovative patient monitoring technologies, along with his dedication to enhancing patient lives, aligns perfectly with our mission. Together, we will advance the future of limb health through the first ever continuous perfusion sensing technology (CPST)."

Kiani is widely known for founding Masimo, a global medical technology company whose non-invasive monitoring solutions, including pulse oximetry, have transformed care delivery and saved countless lives. Beyond Masimo, Kiani is also the founder of the Patient Safety Movement Foundation, a global non-profit dedicated to eliminating preventable deaths in healthcare. His career reflects a steadfast commitment to leveraging technology to improve outcomes, reduce variability in care, and ensure that patients everywhere receive the safest and most effective treatment possible.

"MY01's breakthrough CPST Platform^® has been shown to help clinicians save limbs and lives by detecting the lack of perfusion to the limb after an injury in time to save the limb," added Kiani. "Over 1 million limb injuries occur annually and without the MY01 CPST platform, clinicians have to make very hard choices with very little data. CPST is a game changer. In a recent study of 100 patients, clinicians were able to make a diagnosis 4 hours earlier than traditional methods with 100% efficacy. MY01's CPST platform should be in every emergency room. I look forward to supporting MY01's mission to improve patient lives around the world."

With this investment, MY01 will continue the expansion of its CPST Platform^®, aimed at reducing variation in orthopedic and vascular trauma care.The company also plans to pioneer advancements in cardiogenic shock monitoring, providing physicians with new tools to optimize outcomes for critically ill patients.

To learn more, visit my01.io 

About MY01
Founded in 2019 and based in Montreal, MY01 envisions a world where every disease is quantifiable, enabling precise and personalized care for all patients. Its CPST Platform^® transforms trauma programs by converting complex biological signs into dynamic, actionable, real-time data that empowers better decision-making. This innovation reduces care variability and improves outcomes while helping hospitals allocate resources more efficiently. MY01 is currently operational in the USA, Europe, and Canada, setting new standards in healthcare.

Media Contact:
Interdependence Public Relations
(949) 777-2468
[email protected]

*Balhareth MA, Vaile K, Schneider P, Liew A, Hall J, Guy P, Lawendy AR, Doornberg J, Jaarsma R, Leighton R. Clinical trial of a new continuous compartment pressure monitoring to aid in the diagnosis of Acute Compartment Syndrome. J Orthop Trauma. 2025 Apr 8. doi: 10.1097/BOT.0000000000002980. Epub ahead of print. PMID: 40197600.

SOURCE My01